市場調査レポート
商品コード
1300105

特発性肺線維症の世界市場:薬剤タイプ別、投与経路別、流通チャネル別、地域別、国別の分析、市場考察、予測

Global Idiopathic Pulmonary Fibrosis Market : Analysis By Drug Type, Route of Administration, Distribution Channel, By Region, By Country: Market Insights and Forecast

出版日: | 発行: Azoth Analytics | ページ情報: 英文 260 Pages | 納期: 即納可能 即納可能とは

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=154.09円
特発性肺線維症の世界市場:薬剤タイプ別、投与経路別、流通チャネル別、地域別、国別の分析、市場考察、予測
出版日: 2023年07月01日
発行: Azoth Analytics
ページ情報: 英文 260 Pages
納期: 即納可能 即納可能とは
  • 全表示
  • 概要
  • 図表
  • 目次
概要

世界の特発性肺線維症の市場規模は、2022年の43億9,000万米ドルから2029年末までに106億4,000万米ドルに達し、予測期間の2024年~2029年にCAGRで46.3%の成長が予測されています。

当レポートでは、世界の特発性肺線維症市場について調査し、市場規模と予測、地域とセグメントの分析、主な動向と機会などの情報を提供しています。

目次

第1章 市場の背景

  • 範囲と製品の見通し
  • エグゼクティブサマリー
  • 調査手法

第2章 戦略的推奨事項

  • 新たな治療法の開発に向けた研究開発体制の強化
  • 治療へのアクセスの改善

第3章 世界の特発性肺線維症市場:実績と予測

  • 特発性肺線維症市場に対するマクロ経済要因の影響の分析
  • もっとも複雑なIPFの症状
  • 特発性肺線維症の診断済み有病症例
  • パイプラインにおけるIPF治療薬の競合情勢
  • IPFによる慢性咳嗽
  • 特発性肺線維症:ファクトシート
  • IPFによる慢性咳嗽の病態生理学
  • IPFにおける慢性咳嗽に関連する併存疾患
  • 世界の特発性肺線維症市場:ダッシュボード
  • 世界の特発性肺線維症市場:市場金額の評価(2018年~2028年)
  • 世界の特発性肺線維症市場に対するCOVID-19の影響
  • 世界の特発性肺線維症市場セグメンテーション:薬剤タイプ別
  • 世界の特発性肺線維症市場セグメンテーション:投与経路別
  • 世界の特発性肺線維症市場セグメンテーション:流通チャネル別

第4章 世界の特発性肺線維症市場、地域分析

  • 研究の地域の範囲

第5章 南北アメリカの特発性肺線維症市場:実績と予測(2018年~2028年)

  • 南北アメリカの特発性肺線維症市場:スナップショット
  • 南北アメリカの特発性肺線維症市場:市場規模とCAGR(2018年~2028年)
  • 南北アメリカの特発性肺線維症市場:主な要因
  • 南北アメリカの特発性肺線維症市場セグメンテーション:薬剤タイプ別
  • 南北アメリカの特発性肺線維症市場セグメンテーション:投与経路別
  • 南北アメリカの特発性肺線維症市場セグメンテーション:流通チャネル別
  • 南北アメリカの特発性肺線維症市場セグメンテーション:国別
    • 米国の特発性肺線維症市場:市場規模とCAGR(2018年~2028年)
    • カナダの特発性肺線維症市場:市場規模とCAGR(2018年~2028年)
    • その他の南北アメリカの特発性肺線維症市場:市場規模とCAGR(2018年~2028年)

第6章 欧州の特発性肺線維症市場:実績と予測(2018年~2028年)

  • 欧州の特発性肺線維症市場:スナップショット
  • 欧州の特発性肺線維症市場:市場規模とCAGR(2018年~2028年)
  • 欧州の特発性肺線維症市場:主な要因
  • 欧州の特発性肺線維症市場セグメンテーション:薬剤タイプ別
  • 欧州の特発性肺線維症市場セグメンテーション:投与経路別
  • 欧州の特発性肺線維症市場セグメンテーション:流通チャネル別
  • 欧州の特発性肺線維症市場セグメンテーション:国別
    • フランスの特発性肺線維症市場:市場規模とCAGR(2018年~2028年)
    • 英国の特発性肺線維症市場:市場規模とCAGR(2018年~2028年)
    • イタリアの特発性肺線維症市場:市場規模とCAGR(2018年~2028年)
    • スペインの特発性肺線維症市場:市場規模とCAGR(2018年~2028年)
    • ドイツの特発性肺線維症市場:市場規模とCAGR(2018年~2028年)
    • その他の欧州の特発性肺線維症市場:市場規模とCAGR(2018年~2028年)

第7章 アジア太平洋の特発性肺線維症市場:実績と予測(2018年~2028年)

  • アジア太平洋の特発性肺線維症市場:スナップショット
  • アジア太平洋の特発性肺線維症市場:市場規模とCAGR(2018年~2028年)
  • アジア太平洋の特発性肺線維症市場:主な要因
  • アジア太平洋の特発性肺線維症市場セグメンテーション:薬剤タイプ別
  • アジア太平洋の特発性肺線維症市場セグメンテーション:投与経路別
  • アジア太平洋の特発性肺線維症市場セグメンテーション:流通チャネル別
  • アジア太平洋の特発性肺線維症市場セグメンテーション:国別
    • 中国の特発性肺線維症市場:市場規模とCAGR(2018年~2028年)
    • 日本の特発性肺線維症市場:市場規模とCAGR(2018年~2028年)
    • 韓国の特発性肺線維症市場:市場規模とCAGR(2018年~2028年)
    • インドの特発性肺線維症市場:市場規模とCAGR(2018年~2028年)
    • その他のアジア太平洋の特発性肺線維症市場:市場規模とCAGR(2018年~2028年)

第8章 中東・アフリカの特発性肺線維症市場:実績と予測(2018年~2028年)

  • 中東・アフリカの特発性肺線維症市場:スナップショット
  • 中東・アフリカの特発性肺線維症市場:市場規模とCAGR(2018年~2028年)
  • 中東・アフリカの特発性肺線維症市場:主な要因
  • 中東・アフリカの特発性肺線維症市場セグメンテーション:薬剤タイプ別
  • 中東・アフリカの特発性肺線維症市場セグメンテーション:投与経路別
  • 中東・アフリカの特発性肺線維症市場セグメンテーション:流通チャネル別

第9章 市場力学

  • 世界の特発性肺線維症市場に対する市場力学の影響の評価
  • 促進要因
  • 抑制要因
  • 動向

第10章 業界エコシステム分析

  • マクロ経済要因の評価
  • ポーターのファイブフォースモデル

第11章 競合ポジショニング

  • 企業の製品ポジショニング
  • 市場ポジションマトリックス
  • 特発性肺線維症市場の市場シェア分析
  • 企業プロファイル
    • Boehringer Ingelheim
    • F. Hoffmann-La Roche AG
    • Cipla Ltd.
    • Shionogi & Co., Ltd.
    • Bristol-Myers Squibb Co.
    • United Therapeutics
    • FibroGen, Inc.
    • Pliant Therapeutics
    • Galecto Inc.
    • CSL Behring
図表

List of Figures

List of Figures

  • Figure 1: Most bothersome IPF symptom
  • Figure 2: Global IPF diagnosed prevalent cases,2023 (Millions)
  • Figure 3: Global Idiopathic Pulmonary Fibrosis Market Size, By Value, 2019-2022 (USD Million)
  • Figure 4: Global Idiopathic Pulmonary Fibrosis Market Size, By Value, 2023-2029 (USD Million)
  • Figure 5: Global Idiopathic Pulmonary Fibrosis Market Share, By Drug Type, 2022 (%)
  • Figure 6: Global Idiopathic Pulmonary Fibrosis Market Size, By Pirfenidone, By Value, 2019H-2029F (USD Million & CAGR)
  • Figure 7: Global Idiopathic Pulmonary Fibrosis Market Absolute Opportunity, By Pirfenidone, 2019-2029 (USD Million)
  • Figure 8: Global Idiopathic Pulmonary Fibrosis Market Size, By Nintedanib, By Value, 2019H-2029F (USD Million & CAGR)
  • Figure 9: Global Idiopathic Pulmonary Fibrosis Market Absolute Opportunity, By Nintedanib, 2019-2029 (USD Million)
  • Figure 10: Global Idiopathic Pulmonary Fibrosis Market Size, By Other drugs, By Value, 2019H-2029F (USD Million & CAGR)
  • Figure 11: Global Idiopathic Pulmonary Fibrosis Market Absolute Opportunity, By Other drugs, 2019-2029 (USD Million)
  • Figure 12: Global Idiopathic Pulmonary Fibrosis Market Size, By Oral, By Value, 2019H-2029F (USD Million & CAGR)
  • Figure 13: Global Idiopathic Pulmonary Fibrosis Market Absolute Opportunity, By Oral, 2019-2029 (USD Million)
  • Figure 14: Global Idiopathic Pulmonary Fibrosis Market Size, By Parenteral, By Value, 2019H-2029F (USD Million & CAGR)
  • Figure 15: Global Idiopathic Pulmonary Fibrosis Market Absolute Opportunity, By Parenteral, 2019-2029 (USD Million)
  • Figure 16: Global Idiopathic Pulmonary Fibrosis Market Size, By Other ROA, By Value, 2019H-2029F (USD Million & CAGR)`
  • Figure 17: Global Idiopathic Pulmonary Fibrosis Market Absolute Opportunity, By Other ROA, 2019-2029 (USD Million)
  • Figure 18: Global Idiopathic Pulmonary Fibrosis Market Size, By Hospital Pharmacies, By Value, 2019H-2029F (USD Million & CAGR)
  • Figure 19: Global Idiopathic Pulmonary Fibrosis Market Absolute Opportunity, By Hospital Pharmacies, 2019-2029 (USD Million)
  • Figure 20: Global Idiopathic Pulmonary Fibrosis Market Size, By Retail Pharmacies, By Value, 2019H-2029F (USD Million & CAGR)
  • Figure 21: Global Idiopathic Pulmonary Fibrosis Market Absolute Opportunity, By Retail Pharmacies, 2019-2029 (USD Million)
  • Figure 22: Global Idiopathic Pulmonary Fibrosis Market Size, By Online Channel, By Value, 2019H-2029F (USD Million & CAGR)
  • Figure 23: Global Idiopathic Pulmonary Fibrosis Market Absolute Opportunity, By Online Channel, 2019-2029 (USD Million)
  • Figure 24: Americas Idiopathic Pulmonary Fibrosis Market Size, By Value, 2019H-2029F (USD Million)
  • Figure 25: Americas Idiopathic Pulmonary Fibrosis Market Share, By Drug Type, 2022 (%)
  • Figure 26: Americas Idiopathic Pulmonary Fibrosis Market, By Pirfenidone, By Value, 2019H-2029F (USD Million & CAGR)
  • Figure 27: Americas Idiopathic Pulmonary Fibrosis Market, By Nintedanib, By Value, 2019H-2029F (USD Million & CAGR)
  • Figure 28: Americas Idiopathic Pulmonary Fibrosis Market, By Other drugs, By Value, 2019H-2029F (USD Million & CAGR)
  • Figure 29: Americas Idiopathic Pulmonary Fibrosis Market, By Oral, By Value, 2019H-2029F (USD Million & CAGR)
  • Figure 30: Americas Idiopathic Pulmonary Fibrosis Market, By Parenteral, By Value, 2019H-2029F (USD Million & CAGR)
  • Figure 31: Americas Idiopathic Pulmonary Fibrosis Market, By Other ROA, By Value, 2019H-2029F (USD Million & CAGR)
  • Figure 32: Americas Idiopathic Pulmonary Fibrosis Market, By Hospital Pharmacies, By Value, 2019H-2029F (USD Million & CAGR)
  • Figure 33: Americas Idiopathic Pulmonary Fibrosis Market, By Retail Pharmacies, By Value, 2019H-2029F (USD Million & CAGR)
  • Figure 34: Americas Idiopathic Pulmonary Fibrosis Market, By Online Channel, By Value, 2019H-2029F (USD Million & CAGR)
  • Figure 35: United States Idiopathic Pulmonary Fibrosis Market, By Value, 2019-2029 (USD Million & CAGR)
  • Figure 36: United States Idiopathic Pulmonary Fibrosis Market Value, By Drug Type, 2022 (USD Million)
  • Figure 37: United States Idiopathic Pulmonary Fibrosis Market Share, By Drug Type, By Value, 2022 (%)
  • Figure 38: United States Idiopathic Pulmonary Fibrosis Market Share, By Route of Administration, By Value, 2022 (%)
  • Figure 39: United States Idiopathic Pulmonary Fibrosis Market Share, By Distribution Channel, 2022 (%)
  • Figure 40: Canada Idiopathic Pulmonary Fibrosis Market, By Value, 2019-2029 (USD Million & CAGR)
  • Figure 41: Canada Idiopathic Pulmonary Fibrosis Market Value, By Drug Type, 2022 (USD Million)
  • Figure 42: Canada Idiopathic Pulmonary Fibrosis Market Share, By Drug Type, By Value, 2022 (%)
  • Figure 43: Canada Idiopathic Pulmonary Fibrosis Market Share, By Route of Administration, 2022 (%)
  • Figure 44: Canada Idiopathic Pulmonary Fibrosis Market Share, Distribution Channel, 2022 (%)
  • Figure 45: Rest of Americas Idiopathic Pulmonary Fibrosis Market, By Value, 2019-2029 (USD Million & CAGR)
  • Figure 46: Rest of Americas Idiopathic Pulmonary Fibrosis Market Value, By Drug Type, 2022 (USD Million)
  • Figure 47: Rest of Americas Idiopathic Pulmonary Fibrosis Market Share, By Drug Type, By Value, 2022 (%)
  • Figure 48: Rest of Americas Idiopathic Pulmonary Fibrosis Market Share, By Route of Administration, 2022 (%)
  • Figure 49: Rest of Americas Idiopathic Pulmonary Fibrosis Market Share, By Distribution Channel, 2022 (%)
  • Figure 50: Europe Idiopathic Pulmonary Fibrosis Market Size, By Value, 2019H-2029F (USD Million)
  • Figure 51: Europe Idiopathic Pulmonary Fibrosis Market Share, By Drug Type, 2022 (%)
  • Figure 52: Europe Idiopathic Pulmonary Fibrosis Market, By Pirfenidone, By Value, 2019H-2029F (USD Million & CAGR)
  • Figure 53: Europe Idiopathic Pulmonary Fibrosis Market, By Nintedanib, By Value, 2019H-2029F (USD Million & CAGR)
  • Figure 54: Europe Idiopathic Pulmonary Fibrosis Market, By Other drugs, By Value, 2019H-2029F (USD Million & CAGR)
  • Figure 55: Europe Idiopathic Pulmonary Fibrosis Market, By Oral, By Value, 2019H-2029F (USD Million & CAGR)
  • Figure 56: Europe Idiopathic Pulmonary Fibrosis Market, By Parenteral, By Value, 2019H-2029F (USD Million & CAGR)
  • Figure 57: Europe Idiopathic Pulmonary Fibrosis Market, By Other ROA, By Value, 2019H-2029F (USD Million & CAGR)
  • Figure 58: Europe Idiopathic Pulmonary Fibrosis Market, By Hospital Pharmacies, By Value, 2019H-2029F (USD Million & CAGR)
  • Figure 59: Europe Idiopathic Pulmonary Fibrosis Market, By Retail Pharmacies, By Value, 2019H-2029F (USD Million & CAGR)
  • Figure 60: Europe Idiopathic Pulmonary Fibrosis Market, By Online Channel, By Value, 2019H-2029F (USD Million & CAGR)
  • Figure 61: France Idiopathic Pulmonary Fibrosis Market, By Value, 2019-2029 (USD Million & CAGR)
  • Figure 62: France Idiopathic Pulmonary Fibrosis Market Value, By Drug Type, 2022 (USD Million)
  • Figure 63: France Idiopathic Pulmonary Fibrosis Market Share, By Drug Type, By Value, 2022 (%)
  • Figure 64: France Idiopathic Pulmonary Fibrosis Market Share, By Route of Administration, 2022 (%)
  • Figure 65: France Idiopathic Pulmonary Fibrosis Market Share, By Distribution Channel, 2022 (%)
  • Figure 66: United Kingdom Idiopathic Pulmonary Fibrosis Market, By Value, 2019-2029 (USD Million & CAGR)
  • Figure 67: United Kingdom Idiopathic Pulmonary Fibrosis Market Value, By Drug Type, 2022 (USD Million)
  • Figure 68: United Kingdom Idiopathic Pulmonary Fibrosis Market Share, By Drug Type, By Value, 2022 (%)
  • Figure 69: United Kingdom Idiopathic Pulmonary Fibrosis Market Share, By Route of Administration, 2022 (%)
  • Figure 70: United Kingdom Idiopathic Pulmonary Fibrosis Market Share, By Distribution Channel, 2022 (%)
  • Figure 71: Italy Idiopathic Pulmonary Fibrosis Market, By Value, 2019-2029 (USD Million & CAGR)
  • Figure 72: Italy Idiopathic Pulmonary Fibrosis Market Value, By Drug Type, 2022 (USD Million)
  • Figure 73: Italy Idiopathic Pulmonary Fibrosis Market Share, By Drug Type, By Value, 2022 (%)
  • Figure 74: Italy Idiopathic Pulmonary Fibrosis Market Share, By Route of Administration, 2022 (%)
  • Figure 75: Italy Idiopathic Pulmonary Fibrosis Market Share, By Distribution Channel, 2022 (%)
  • Figure 76: Spain Idiopathic Pulmonary Fibrosis Market, By Value, 2019-2029 (USD Million & CAGR)
  • Figure 77: Spain Idiopathic Pulmonary Fibrosis Market Value, By Drug Type, 2022 (USD Million)
  • Figure 78: Spain Idiopathic Pulmonary Fibrosis Market Share, By Drug Type, By Value, 2022 (%)
  • Figure 79: Spain Idiopathic Pulmonary Fibrosis Market Share, By Route of Administration, 2022 (%)
  • Figure 80: Spain Idiopathic Pulmonary Fibrosis Market Share, By Distribution Channel, 2022 (%)
  • Figure 81: Germany Idiopathic Pulmonary Fibrosis Market, By Value, 2019-2029 (USD Million & CAGR)
  • Figure 82: Germany Idiopathic Pulmonary Fibrosis Market Value, By Drug Type, 2022 (USD Million)
  • Figure 83: Germany Idiopathic Pulmonary Fibrosis Market Share, By Drug Type, By Value, 2022 (%)
  • Figure 84: Germany Idiopathic Pulmonary Fibrosis Market Share, By Route of Administration, 2022 (%)
  • Figure 85: Germany Idiopathic Pulmonary Fibrosis Market Share, By Distribution Channel, 2022 (%)
  • Figure 86: Rest of Europe Idiopathic Pulmonary Fibrosis Market, By Value, 2019-2029 (USD Million & CAGR)
  • Figure 87: Rest of Europe Idiopathic Pulmonary Fibrosis Market Value, By Drug Type, 2022 (USD Million)
  • Figure 88: Rest of Europe Idiopathic Pulmonary Fibrosis Market Share, By Drug Type, By Value, 2022 (%)
  • Figure 89: Rest of Europe Idiopathic Pulmonary Fibrosis Market Share, By Route of Administration, 2022 (%)
  • Figure 90: Rest of Europe Idiopathic Pulmonary Fibrosis Market Share, By Distribution Channel, 2022 (%)
  • Figure 91: Asia Pacific Idiopathic Pulmonary Fibrosis Market Size, By Value, 2019H-2029F (USD Million)
  • Figure 92: Asia Pacific Idiopathic Pulmonary Fibrosis Market Share, By Drug Type, 2022 (%)
  • Figure 93: Asia Pacific Idiopathic Pulmonary Fibrosis Market, By Pirfenidone, By Value, 2019H-2029F (USD Million & CAGR)
  • Figure 94: Asia Pacific Idiopathic Pulmonary Fibrosis Market, By Nintedanib, By Value, 2019H-2029F (USD Million & CAGR)
  • Figure 95: Asia Pacific Idiopathic Pulmonary Fibrosis Market, By Other drugs, By Value, 2019H-2029F (USD Million & CAGR)
  • Figure 96: Asia Pacific Idiopathic Pulmonary Fibrosis Market, By Oral, By Value, 2019H-2029F (USD Million & CAGR)
  • Figure 97: Asia Pacific Idiopathic Pulmonary Fibrosis Market, By Parenteral, By Value, 2019H-2029F (USD Million & CAGR)
  • Figure 98: Asia Pacific Idiopathic Pulmonary Fibrosis Market, By Other ROA, By Value, 2019H-2029F (USD Million & CAGR)
  • Figure 99: Asia Pacific Idiopathic Pulmonary Fibrosis Market, By Hospital Pharmacies, By Value, 2019H-2029F (USD Million & CAGR)
  • Figure 100: Asia Pacific Idiopathic Pulmonary Fibrosis Market, By Retail Pharmacies, By Value, 2019H-2029F (USD Million & CAGR)
  • Figure 101: Asia Pacific Idiopathic Pulmonary Fibrosis Market, By Online Channel, By Value, 2019H-2029F (USD Million & CAGR)
  • Figure 102: China Idiopathic Pulmonary Fibrosis Market, By Value, 2019-2029 (USD Million & CAGR)
  • Figure 103: China Idiopathic Pulmonary Fibrosis Market Value, By Drug Type, 2022 (USD Million)
  • Figure 104: China Idiopathic Pulmonary Fibrosis Market Share, By Drug Type, By Value, 2022 (%)
  • Figure 105: China Idiopathic Pulmonary Fibrosis Market Share, By Route of Administration, 2022 (%)
  • Figure 106: China Idiopathic Pulmonary Fibrosis Market Share, By Distribution Channel, 2022 (%)
  • Figure 107: Japan Idiopathic Pulmonary Fibrosis Market, By Value, 2019-2029 (USD Million & CAGR)
  • Figure 108: Japan Idiopathic Pulmonary Fibrosis Market Value, By Drug Type, 2022 (USD Million)
  • Figure 109: Japan Idiopathic Pulmonary Fibrosis Market Share, By Drug Type, By Value, 2022 (%)
  • Figure 110: Japan Idiopathic Pulmonary Fibrosis Market Share, By Route of Administration, 2022 (%)
  • Figure 111: Japan Idiopathic Pulmonary Fibrosis Market Share, By Distribution Channel, 2022 (%)
  • Figure 112: South Korea Idiopathic Pulmonary Fibrosis Market, By Value, 2019-2029 (USD Million & CAGR)
  • Figure 113: South Korea Idiopathic Pulmonary Fibrosis Market Value, By Drug Type, 2022 (USD Million)
  • Figure 114: South Korea Idiopathic Pulmonary Fibrosis Market Share, By Drug Type, By Value, 2022 (%)
  • Figure 115: South Korea Idiopathic Pulmonary Fibrosis Market Share, By Route of Administration, 2022 (%)
  • Figure 116: South Korea Idiopathic Pulmonary Fibrosis Market Share, By Distribution Channel, 2022 (%)
  • Figure 117: India Idiopathic Pulmonary Fibrosis Market, By Value, 2019-2029 (USD Million & CAGR)
  • Figure 118: India Idiopathic Pulmonary Fibrosis Market Value, By Drug Type, 2022 (USD Million)
  • Figure 119: India Idiopathic Pulmonary Fibrosis Market Share, By Drug Type, By Value, 2022 (%)
  • Figure 120: India Idiopathic Pulmonary Fibrosis Market Share, By Route of Administration, 2022 (%)
  • Figure 121: India Idiopathic Pulmonary Fibrosis Market Share, Distribution Channel, 2022 (%)
  • Figure 122: Rest of Asia Pacific Idiopathic Pulmonary Fibrosis Market, By Value, 2019-2029 (USD Million & CAGR)
  • Figure 123: Rest of Asia Pacific Idiopathic Pulmonary Fibrosis Market Value, By Drug Type, 2022 (USD Million)
  • Figure 124: Rest of Asia Pacific Idiopathic Pulmonary Fibrosis Market Share, By Drug Type, By Value, 2022 (%)
  • Figure 125: Rest of Asia Pacific Idiopathic Pulmonary Fibrosis Market Share, By Route of Administration, 2022 (%)
  • Figure 126: Rest of Asia Pacific Idiopathic Pulmonary Fibrosis Market Share, By Distribution Channel, 2022 (%)
  • Figure 127: Middle East and Africa Idiopathic Pulmonary Fibrosis Market Size, By Value, 2019H-2029F (USD Million)
  • Figure 128: Middle East and Africa Idiopathic Pulmonary Fibrosis Market Share, By Drug Type, 2022 (%)
  • Figure 129: Middle East and Africa Idiopathic Pulmonary Fibrosis Market, By Pirfenidone, By Value, 2019H-2029F (USD Million & CAGR)
  • Figure 130 Middle East and Africa Idiopathic Pulmonary Fibrosis Market, By Nintedanib, By Value, 2019H-2029F (USD Million & CAGR)
  • Figure 131 Middle East and Africa Idiopathic Pulmonary Fibrosis Market, By Other drugs, By Value, 2019H-2029F (USD Million & CAGR)
  • Figure 132: Middle East and Africa Idiopathic Pulmonary Fibrosis Market, By Oral, By Value, 2019H-2029F (USD Million & CAGR)
  • Figure 133: Middle East and Africa Idiopathic Pulmonary Fibrosis Market, By Parenteral, By Value, 2019H-2029F (USD Million & CAGR)
  • Figure 134: Middle East and Africa Idiopathic Pulmonary Fibrosis Market, By Other ROA, By Value, 2019H-2029F (USD Million & CAGR)
  • Figure 135: Middle East and Africa Idiopathic Pulmonary Fibrosis Market, By Hospital Pharmacies, By Value, 2019H-2029F (USD Million & CAGR)
  • Figure 136: Middle East and Africa Idiopathic Pulmonary Fibrosis Market, By Retail Pharmacies, By Value, 2019H-2029F (USD Million & CAGR)
  • Figure 137: Middle East and Africa Idiopathic Pulmonary Fibrosis Market, By Online Channel, By Value, 2019H-2029F (USD Million & CAGR)
  • Figure 138: Global Impact of Drivers and Restraints
  • Figure 139: Market Share of Prominent Companies of Idiopathic Pulmonary Fibrosis Market, 2022 (%)
  • Figure 140: Roche Revenues, 2020-2022 (USD Million)
  • Figure 141: Roche Revenue , By Business Segment, 2022 (%)
  • Figure 142: Cipla Revenues, 2020-2022 (USD Million)
  • Figure 143: Cipla Revenues, By Geographic Segments, 2022 (%)
  • Figure 144: Cipla Revenue , By Business Segments, 2022 (%)
  • Figure 145: Shionogi & Co., Revenues, 2020-2022 (USD Million)
  • Figure 146: Shionogi & Co., Revenues, By Geographic Segments, 2022 (%)
  • Figure 147: Shionogi & Co., Revenue , By Therapeutic Area, 2022 (%)
  • Figure 148: Bristol-Myers Squibb Revenues, 2020-2022 (USD Million)
  • Figure 149: Bristol-Myers Squibb Revenues, By Geographic Segments, 2022 (%)
  • Figure 150: United Therapeutics Revenues, 2020-2022 (USD Million)
  • Figure 151: United Therapeutics Revenues, By Geographic Segments, 2022 (%)
  • Figure 152: United Therapeutics Revenues, By commercial products, 2022 (%)
  • Figure 153: Pliant Therapeutics Revenues, 2020-2022 (USD Thousand)
  • Figure 154: CSL Behring Revenues, 2020-2022 (USD Million)
  • Figure 155: CSL Behring Revenues, By Geographic Segments, 2022 (%)
  • Figure 156: CSL Behring Revenue , By Therapeutic Area, 2022 (%)

List of Tables

Table A1: Global Impact of Macro Economic Factors, By Region

Table A2: Competitive landscape for IPF drugs in Pipeline

Table A3: Unmet need of Patients with Chronic Cough

Table A4: Comorbid conditions associated with chronic cough in patients with IPF.

Table A5: United States Idiopathic Pulmonary Fibrosis Market, By Drug Type, By Value, 2019-2022 (USD Million)

Table A6: United States Idiopathic Pulmonary Fibrosis Market, By Drug Type, By Value, 2023-2029 (USD Million)

Table A7: United States Idiopathic Pulmonary Fibrosis Market, By Route of Administration, By Value, 2019-2022 (USD Million)

Table A8: United States Idiopathic Pulmonary Fibrosis Market, By Route of Administration, By Value, 2023-2029 (USD Million)

Table A9: United States Idiopathic Pulmonary Fibrosis Market, By Distribution Channel, By Value, 2019-2022 (USD Million)

Table A10: United States Idiopathic Pulmonary Fibrosis Market, By Distribution Channel, By Value, 2023-2029 (USD Million)

Table A11: Canada Idiopathic Pulmonary Fibrosis Market, By Drug Type, By Value, 2019-2022 (USD Million)

Table A12: Canada Idiopathic Pulmonary Fibrosis Market, By Drug Type, By Value, 2023-2029 (USD Million)

Table A13: Canada Idiopathic Pulmonary Fibrosis Market, By Route of Administration, By Value, 2019-2022 (USD Million)

Table A14: Canada Idiopathic Pulmonary Fibrosis Market, By Route of Administration, By Value, 2023-2029 (USD Million)

Table A15: Canada Idiopathic Pulmonary Fibrosis Market, By Distribution Channel, By Value, 2019-2022 (USD Million)

Table A16: Canada Idiopathic Pulmonary Fibrosis Market, By Distribution Channel, By Value, 2023-2029 (USD Million)

Table A17: Rest of Americas Idiopathic Pulmonary Fibrosis Market, By Drug Type, By Value, 2019-2022 (USD Million)

Table A18: Rest of Americas Idiopathic Pulmonary Fibrosis Market, By Drug Type, By Value, 2023-2029 (USD Million)

Table A19: Rest of Americas Idiopathic Pulmonary Fibrosis Market, By Route of Administration, By Value, 2019-2022 (USD Million)

Table A20: Rest of Americas Idiopathic Pulmonary Fibrosis Market, By Route of Administration, By Value, 2023-2029 (USD Million)

Table A21: Rest of Americas Idiopathic Pulmonary Fibrosis Market, By Distribution Channel, By Value, 2019-2022 (USD Million)

Table A22: Rest of Americas Idiopathic Pulmonary Fibrosis Market, By Distribution Channel, By Value, 2023-2029 (USD Million)

Table A23: France Idiopathic Pulmonary Fibrosis Market, By Drug Type, By Value, 2019-2022 (USD Million)

Table A24: France Idiopathic Pulmonary Fibrosis Market, By Drug Type, By Value, 2023-2029 (USD Million)

Table A25: France Idiopathic Pulmonary Fibrosis Market, By Route of Administration, By Value, 2019-2022 (USD Million)

Table A26: France Idiopathic Pulmonary Fibrosis Market, By Route of Administration, By Value, 2023-2029 (USD Million)

Table A27: France Idiopathic Pulmonary Fibrosis Market, By Distribution Channel, By Value, 2019-2022 (USD Million)

Table A28: France Idiopathic Pulmonary Fibrosis Market, By Distribution Channel, By Value, 2023-2029 (USD Million)

Table A29: United Kingdom Idiopathic Pulmonary Fibrosis Market, By Drug Type, By Value, 2019-2022 (USD Million

Table A30: United Kingdom Idiopathic Pulmonary Fibrosis Market, By Drug Type, By Value, 2023-2029 (USD Million)

Table A31: United Kingdom Idiopathic Pulmonary Fibrosis Market, By Route of Administration, By Value, 2019-2022 (USD Million)

Table A32: United Kingdom Idiopathic Pulmonary Fibrosis Market, By Route of Administration, By Value, 2023-2029 (USD Million)

Table A33: United Kingdom Idiopathic Pulmonary Fibrosis Market, By Distribution Channel, By Value, 2019-2022 (USD Million)

Table A34: United Kingdom Idiopathic Pulmonary Fibrosis Market, By Distribution Channel, By Value, 2023-2029 (USD Million)

Table A35: Italy Idiopathic Pulmonary Fibrosis Market, By Drug Type, By Value, 2019-2022 (USD Million)

Table A36: Italy Idiopathic Pulmonary Fibrosis Market, By Drug Type, By Value, 2023-2029 (USD Million)

Table A37: Italy Idiopathic Pulmonary Fibrosis Market, By Route of Administration, By Value, 2019-2022 (USD Million)

Table A38: Italy Idiopathic Pulmonary Fibrosis Market, By Route of Administration, By Value, 2023-2029 (USD Million)

Table A39: Italy Idiopathic Pulmonary Fibrosis Market, By Distribution Channel, By Value, 2019-2022 (USD Million)

Table A40: Italy Idiopathic Pulmonary Fibrosis Market, By Distribution Channel, By Value, 2023-2029 (USD Million)

Table A41: Spain Idiopathic Pulmonary Fibrosis Market, By Drug Type, By Value, 2019-2022 (USD Million)

Table A42: Spain Idiopathic Pulmonary Fibrosis Market, By Drug Type, By Value, 2023-2029 (USD Million)

Table A43: Spain Idiopathic Pulmonary Fibrosis Market, By Route of Administration, By Value, 2019-2022 (USD Million)

Table A44: Spain Idiopathic Pulmonary Fibrosis Market, By Route of Administration, By Value, 2023-2029 (USD Million)

Table A45: Spain Idiopathic Pulmonary Fibrosis Market, By Distribution Channel, By Value, 2019-2022 (USD Million)

Table A46: Spain Idiopathic Pulmonary Fibrosis Market, By Distribution Channel, By Value, 2023-2029 (USD Million)

Table A47: Germany Idiopathic Pulmonary Fibrosis Market, By Drug Type, By Value, 2019-2022 (USD Million)

Table A48: Germany Idiopathic Pulmonary Fibrosis Market, By Drug Type, By Value, 2023-2029 (USD Million)

Table A49: Germany Idiopathic Pulmonary Fibrosis Market, By Route of Administration, By Value, 2019-2022 (USD Million)

Table A50: Germany Idiopathic Pulmonary Fibrosis Market, By Route of Administration, By Value, 2023-2029 (USD Million)

Table A51: Germany Idiopathic Pulmonary Fibrosis Market, By Distribution Channel, By Value, 2019-2022 (USD Million)

Table A52: Germany Idiopathic Pulmonary Fibrosis Market, By Distribution Channel, By Value, 2023-2029 (USD Million)

Table A53: Rest of Europe Idiopathic Pulmonary Fibrosis Market, By Drug Type, By Value, 2019-2022 (USD Million)

Table A54: Rest of Europe Idiopathic Pulmonary Fibrosis Market, By Drug Type, By Value, 2023-2029 (USD Million)

Table A55: Rest of Europe Idiopathic Pulmonary Fibrosis Market, By Route of Administration, By Value, 2019-2022 (USD Million)

Table A56: Rest of Europe Idiopathic Pulmonary Fibrosis Market, By Route of Administration, By Value, 2023-2029 (USD Million)

Table A57: Rest of Europe Idiopathic Pulmonary Fibrosis Market, By Distribution Channel, By Value, 2019-2022 (USD Million)

Table A58: Rest of Europe Idiopathic Pulmonary Fibrosis Market, By Distribution Channel, By Value, 2023-2029 (USD Million)

Table A59: China Idiopathic Pulmonary Fibrosis Market, By Drug Type, By Value, 2019-2022 (USD Million)

Table A60: China Idiopathic Pulmonary Fibrosis Market, By Drug Type, By Value, 2023-2029 (USD Million)

Table A61: China Idiopathic Pulmonary Fibrosis Market, By Route of Administration, By Value, 2019-2022 (USD Million)

Table A62: China Idiopathic Pulmonary Fibrosis Market, By Route of Administration, By Value, 2023-2029 (USD Million)

Table A63: China Idiopathic Pulmonary Fibrosis Market, By Distribution Channel, By Value, 2019-2022 (USD Million)

Table A64: China Idiopathic Pulmonary Fibrosis Market, By Distribution Channel, By Value, 2023-2029 (USD Million)

Table A65: Japan Idiopathic Pulmonary Fibrosis Market, By Drug Type, By Value, 2019-2022 (USD Million)

Table A66: Japan Idiopathic Pulmonary Fibrosis Market, By Drug Type, By Value, 2023-2029 (USD Million)

Table A67: Japan Idiopathic Pulmonary Fibrosis Market, By Route of Administration, By Value, 2019-2022 (USD Million)

Table A68: Japan Idiopathic Pulmonary Fibrosis Market, By Route of Administration, By Value, 2023-2029 (USD Million)

Table A69: Japan Idiopathic Pulmonary Fibrosis Market, By Distribution Channel, By Value, 2019-2022 (USD Million)

Table A70: Japan Idiopathic Pulmonary Fibrosis Market, By Distribution Channel, By Value, 2023-2029 (USD Million)

Table A71: South Korea Idiopathic Pulmonary Fibrosis Market, By Drug Type, By Value, 2019-2022 (USD Million)

Table A72: South Korea Idiopathic Pulmonary Fibrosis Market, By Drug Type, By Value, 2023-2029 (USD Million)

Table A73: South Korea Idiopathic Pulmonary Fibrosis Market, By Route of Administration, By Value, 2019-2022 (USD Million)

Table A74: South Korea Idiopathic Pulmonary Fibrosis Market, By Route of Administration, By Value, 2023-2029 (USD Million)

Table A75: South Korea Idiopathic Pulmonary Fibrosis Market, By Distribution Channel, By Value, 2019-2022 (USD Million)

Table A76: South Korea Idiopathic Pulmonary Fibrosis Market, By Distribution Channel, By Value, 2023-2029 (USD Million)

Table A77: India Idiopathic Pulmonary Fibrosis Market, By Drug Type, By Value, 2019-2022 (USD Million)

Table A78: India Idiopathic Pulmonary Fibrosis Market, By Drug Type, By Value, 2023-2029 (USD Million)

Table A79: India Idiopathic Pulmonary Fibrosis Market, By Route of Administration, By Value, 2019-2022 (USD Million)

Table A80: India Idiopathic Pulmonary Fibrosis Market, By Route of Administration, By Value, 2023-2029 (USD Million)

Table A81: India Idiopathic Pulmonary Fibrosis Market, By Distribution Channel, By Value, 2019-2022 (USD Million)

Table A82: India Idiopathic Pulmonary Fibrosis Market, By Distribution Channel, By Value, 2023-2029 (USD Million)

Table A83: Rest of Asia Pacific Idiopathic Pulmonary Fibrosis Market, By Drug Type, By Value, 2019-2022 (USD Million)

Table A84: Rest of Asia Pacific Idiopathic Pulmonary Fibrosis Market, By Drug Type, By Value, 2023-2029 (USD Million)

Table A85: Rest of Asia Pacific Idiopathic Pulmonary Fibrosis Market, By Route of Administration, By Value, 2019-2022 (USD Million)

Table A86: Rest of Asia Pacific Idiopathic Pulmonary Fibrosis Market, By Route of Administration, By Value, 2023-2029 (USD Million)

Table A87: Rest of Asia Pacific Idiopathic Pulmonary Fibrosis Market, By Distribution Channel, By Value, 2019-2022 (USD Million)

Table A88: Rest of Asia Pacific Idiopathic Pulmonary Fibrosis Market, By Distribution Channel, By Value, 2023-2029 (USD Million)

Table A89: Roche Key Financials, 2020-2022

Table A90: Cipla Key Financials, 2020-2022

Table A91: Shionogi & Co., Key Financials, 2020-2022

Table A92: Bristol-Myers Squibb Key Financials, 2020-2022

Table A93: United Therapeutics Key Financials, 2020-2022

Table A94: Pliant Therapeutics Key Financials, 2020-2022

Table A95: Galecto Key Financials, 2020-2022

Table A96: CSL Behring Key Financials, 2020-2022

目次

Executive Summary

Azoth Analytics has released a research report titled "Idiopathic Pulmonary Fibrosis Market (2023 Edition)" which provides a complete analysis of the global Idiopathic Pulmonary Fibrosis industry in terms of market segmentation by Drug Type (Pirfenidone, Nintedanib, Others), Route of Administration (Oral, Parenteral, Others) and by Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Channel).

The research report covers a detailed analysis of the regions (Americas, Europe, APAC, Middle East Africa) and 11 countries (United States, Canada, Mexico, United Kingdom, Germany, France, Italy, China, India, Japan, South Korea). Additionally, the research report presents data including market size, yearly growth & potential analysis, the competitive study of market players, investment opportunities and demand forecast.

The research study also looks at the market growth indicators, restraints, supply and demand risk, and other important statistics, as well as a full assessment of current and future market trends that are relevant to the market evolution.

During the forecast period, 2024-2029, the Global Idiopathic Pulmonary Fibrosis market is expected to expand at a CAGR of 46.3%. The Global Idiopathic Pulmonary Fibrosis Market is expected to generate USD 10.64 billion by the end of 2029, up from USD 4.39 billion in 2022.

IPF is a life-threatening illness and is both progressive and incurable. Treatments can manage symptoms, limit disease progression, and improve quality of life. Pirfenidone and nintedanib are authorized IPF treatments that slow fibrosis. Severe instances may require lung transplants.

Although IPF is considered a rare disease, its incidence has increased over time. It is estimated that 13 to 20 people per 100,000 are affected globally. The prevalence is higher in older age categories, and the disease is diagnosed more frequently in people over 50. IPF affects both men and women, although men are slightly more susceptible. Ongoing research and clinical trials are investigating novel treatments and potential IPF therapies. Among these are antifibrotic agents, immunomodulatory drugs, and other novel therapeutic approaches that target different pathways implicated in the fibrotic process.

IPF patients need medical follow-ups. Work with interstitial lung disease specialists to create a specific treatment plan and support methods. IPF is characterized by a persistent dry cough, shortness of breath (especially during physical activity), exhaustion, and chest pain. These symptoms typically develop and worsen over time.

Scope of the Report:

  • The report analyses the Idiopathic Pulmonary Fibrosis Market by Value (USD Million).
  • The report presents the analysis of the Idiopathic Pulmonary Fibrosis Market for the historical period of 2019-2022, the estimated year 2023 and the forecast period of 2024-2029.
  • The report analyses the Idiopathic Pulmonary Fibrosis Market by Drug Type (Pirfenidone, Nintedanib, Other drugs).
  • The report analyses the Idiopathic Pulmonary Fibrosis Market by Route of Administration (Oral, Parenteral, Other ROA).
  • The report analyses the Idiopathic Pulmonary Fibrosis Market by Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Channel).
  • The key insights of the report have been presented through the frameworks of SWOT and Porter's Five Forces Analysis. Also, the attractiveness of the market has been presented by region, by services, by mode of operation & by end users.
  • Also, the major opportunities, trends, drivers and challenges of the industry have been analyzed in the report.
  • The report tracks competitive developments, strategies, mergers and acquisitions and new product development. The companies analysed in the report include Boehringer Ingelheim, F. Hoffmann-La Roche AG, Cipla Ltd., Shionogi & Co., Ltd., Bristol-Myers Squibb Co., United Therapeutics, FibroGen, Inc., Pliant Therapeutics, Galecto Inc., CSL Behring

Table of Contents

1. Market Background

  • 1.1 Scope and Product Outlook
  • 1.2 Executive Summary
  • 1.3 Research Methodology

2. Strategic Recommendations

  • 2.1 Enhancing R&D operations for the development of novel treatments
  • 2.2 Improving access to treatment

3. Global Idiopathic Pulmonary Fibrosis Market: Historic and Forecast

  • 3.1 Impact Analysis of Macro Economic Factors on Idiopathic Pulmonary Fibrosis Market
  • 3.2 Most bothersome IPF symptom
  • 3.3 Idiopathic Pulmonary Fibrosis diagnosed prevalent cases
  • 3.4 Competitive Landscape for IPF Drugs in Pipeline
  • 3.5 Chronic Cough due to IPF
  • 3.6 Idiopathic Pulmonary Fibrosis: Fact Sheet
  • 3.7 Pathophysiology of Chronic Cough due to IPF
  • 3.8 Comorbidities Associated with Chronic Cough in IPF
  • 3.9 Global Idiopathic Pulmonary Fibrosis Market: Dashboard
  • 3.10 Global Idiopathic Pulmonary Fibrosis Market: Market Value Assessment, 2018-2028 (USD Million)
  • 3.11 Impact of COVID-19 on Global Idiopathic Pulmonary Fibrosis Market
  • 3.12 Global Idiopathic Pulmonary Fibrosis Market Segmentation: By Drug Type
    • 3.12.1 Global Idiopathic Pulmonary Fibrosis Market, By Drug Type Type Overview
    • 3.12.2 Global Idiopathic Pulmonary Fibrosis Market Size, By Pirfenidone, By Value, 2018H-2028F (USD Million & CAGR)
    • 3.12.3 Global Idiopathic Pulmonary Fibrosis Market Size, By Nintedanib, By Value, 2018H-2028F (USD Million & CAGR)
    • 3.12.4 Global Idiopathic Pulmonary Fibrosis Market Size, By Other drugs, By Value, 2018H-2028F (USD Million & CAGR)
  • 3.13 Global Idiopathic Pulmonary Fibrosis Market Segmentation: By Route of Administration
    • 3.13.1 Global Idiopathic Pulmonary Fibrosis Market, By Route of Administration Overview
    • 3.13.2 Global Idiopathic Pulmonary Fibrosis Market Size, By Oral, By Value, 2018H-2028F (USD Million & CAGR)
    • 3.13.3 Global Idiopathic Pulmonary Fibrosis Market Size, By Parenteral, By Value, 2018H-2028F (USD Million & CAGR)
    • 3.13.4 Global Idiopathic Pulmonary Fibrosis Market Size, By Other ROA, By Value, 2018H-2028F (USD Million & CAGR)
  • 3.14 Global Idiopathic Pulmonary Fibrosis Market Segmentation: By Distribution Channel
    • 3.14.1 Global Idiopathic Pulmonary Fibrosis Market, By Distribution Channel Overview
    • 3.14.2 Global Idiopathic Pulmonary Fibrosis Market Size, By Hospital Pharmacies By Value, 2018H-2028F (USD Million & CAGR)
    • 3.14.3 Global Idiopathic Pulmonary Fibrosis Market Size, By Retail Pharmacies, By Value, 2018H-2028F (USD Million & CAGR)
    • 3.14.4 Global Idiopathic Pulmonary Fibrosis Market Size, By Online Channel, By Value, 2018H-2028F (USD Million & CAGR)

4. Global Idiopathic Pulmonary Fibrosis Market, Regional Analysis

  • 4.1 Regional Coverage of the Study

5. Americas Idiopathic Pulmonary Fibrosis Market: Historic and Forecast (2018-2028)

  • 5.1 Americas Idiopathic Pulmonary Fibrosis Market: Snapshot
  • 5.2 Americas Idiopathic Pulmonary Fibrosis Market: Market Size and CAGR, 2018-2028 (USD Million & CAGR)
  • 5.3 Americas Idiopathic Pulmonary Fibrosis Market: Key Factors
  • 5.4 Americas Idiopathic Pulmonary Fibrosis Market Segmentation: By Drug Type
    • 5.4.1 Americas Idiopathic Pulmonary Fibrosis Market, By Drug Type Overview
    • 5.4.2 Americas Idiopathic Pulmonary Fibrosis Market Size, By Pirfenidone, By Value, 2018H-2028F (USD Million & CAGR)
    • 5.4.3 Americas Idiopathic Pulmonary Fibrosis Market Size, By Nintedanib, By Value, 2018H-2028F (USD Million & CAGR)
    • 5.4.4 Americas Idiopathic Pulmonary Fibrosis Market Size, By Other drugs, By Value, 2018H-2028F (USD Million & CAGR)
  • 5.5 Americas Idiopathic Pulmonary Fibrosis Market Segmentation: By Route of Administration
    • 5.5.1 Americas Idiopathic Pulmonary Fibrosis Market, By Route of Administration Overview
    • 5.5.2 Americas Idiopathic Pulmonary Fibrosis Market Size, By Oral, By Value, 2018H-2028F (USD Million & CAGR)
    • 5.5.3 Americas Idiopathic Pulmonary Fibrosis Market Size, By Parenteral, By Value, 2018H-2028F (USD Million & CAGR)
    • 5.5.4 Americas Idiopathic Pulmonary Fibrosis Market Size, By Other ROA, By Value, 2018H-2028F (USD Million & CAGR)
  • 5.6 Americas Idiopathic Pulmonary Fibrosis Market Segmentation: By Distribution Channel
    • 5.6.1 Americas Idiopathic Pulmonary Fibrosis Market, By Distribution Channel Overview
    • 5.6.2 Americas Idiopathic Pulmonary Fibrosis Market Size, By Hospital Pharmacies, By Value, 2018H-2028F (USD Million & CAGR)
    • 5.6.3 Americas Idiopathic Pulmonary Fibrosis Market Size, By Retail Pharmacies, By Value, 2018H-2028F (USD Million & CAGR)
    • 5.6.4 Americas Idiopathic Pulmonary Fibrosis Market Size, By Online Channel, By Value, 2018H-2028F (USD Million & CAGR)
  • 5.7 Americas Idiopathic Pulmonary Fibrosis Market Segmentation: By Country
    • 5.7.1 United States Idiopathic Pulmonary Fibrosis Market: Market Size and CAGR, 2018-2028 (USD Million & CAGR)
      • 5.7.1.1 United States Idiopathic Pulmonary Fibrosis Market, By Drug Type
      • 5.7.1.2 United States Idiopathic Pulmonary Fibrosis Market, By Route of Administration
      • 5.7.1.3 United States Idiopathic Pulmonary Fibrosis Market, By Distribution Channel
    • 5.7.2 Canada Idiopathic Pulmonary Fibrosis Market: Market Size and CAGR, 2018-2028 (USD Million & CAGR)
      • 5.7.2.1 Canada Idiopathic Pulmonary Fibrosis Market, By Drug Type
      • 5.7.2.2 Canada Idiopathic Pulmonary Fibrosis Market, By Route of Administration
      • 5.7.2.3 Canada Idiopathic Pulmonary Fibrosis Market, By Distribution Channel
    • 5.7.3 Rest of Americas Idiopathic Pulmonary Fibrosis Market: Market Size and CAGR, 2018-2028 (USD Million & CAGR)
      • 5.7.3.1 Rest of Americas Idiopathic Pulmonary Fibrosis Market, By Drug Type
      • 5.7.3.2 Rest of Americas Idiopathic Pulmonary Fibrosis Market, By Route of Administration
      • 5.7.3.3 Rest of Americas Idiopathic Pulmonary Fibrosis Market, By Route of Administration

6. Europe Idiopathic Pulmonary Fibrosis Market: Historic and Forecast (2018-2028)

  • 6.1 Europe Idiopathic Pulmonary Fibrosis Market: Snapshot
  • 6.2 Europe Idiopathic Pulmonary Fibrosis Market: Market Size and CAGR, 2018-2028 (USD Million & CAGR)
  • 6.3 Europe Idiopathic Pulmonary Fibrosis Market: Key Factors
  • 6.4 Europe Idiopathic Pulmonary Fibrosis Market Segmentation: By Drug Type
    • 6.4.1 Europe Idiopathic Pulmonary Fibrosis Market, By Drug Type Overview
    • 6.4.2 Europe Idiopathic Pulmonary Fibrosis Market Size, By Pirfenidone, By Value, 2018H-2028F (USD Million & CAGR)
    • 6.4.3 Europe Idiopathic Pulmonary Fibrosis Market Size, By Nintedanib, By Value, 2018H-2028F (USD Million & CAGR)
    • 6.4.4 Europe Idiopathic Pulmonary Fibrosis Market Size, By Other drugs, By Value, 2018H-2028F (USD Million & CAGR)
  • 6.5 Europe Idiopathic Pulmonary Fibrosis Market Segmentation: By Route of Administration
    • 6.5.1 Europe Idiopathic Pulmonary Fibrosis Market, By Route of Administration Overview
    • 6.5.2 Europe Idiopathic Pulmonary Fibrosis Market Size, By Oral, By Value, 2018H-2028F (USD Million & CAGR)
    • 6.5.3 Europe Idiopathic Pulmonary Fibrosis Market Size, By Parenteral, By Value, 2018H-2028F (USD Million & CAGR)
    • 6.5.4 Europe Idiopathic Pulmonary Fibrosis Market Size, By Other ROA, By Value, 2018H-2028F (USD Million & CAGR)
  • 6.6 Europe Idiopathic Pulmonary Fibrosis Market Segmentation: By Distribution Channel
    • 6.6.1 Europe Idiopathic Pulmonary Fibrosis Market, By Distribution Channel Overview
    • 6.6.2 Europe Idiopathic Pulmonary Fibrosis Market Size, By Hospital Pharmacies, By Value, 2018H-2028F (USD Million & CAGR)
    • 6.6.3 Europe Idiopathic Pulmonary Fibrosis Market Size, By Retail Pharmacies, By Value, 2018H-2028F (USD Million & CAGR)
  • 6.7 Europe Idiopathic Pulmonary Fibrosis Market Segmentation: By Country
    • 6.7.1 France Idiopathic Pulmonary Fibrosis Market: Market Size and CAGR, 2018-2028 (USD Million & CAGR)
      • 6.7.1.1 France Idiopathic Pulmonary Fibrosis Market, By Drug Type
      • 6.7.1.2 France Idiopathic Pulmonary Fibrosis Market, By Route of Administration
      • 6.7.1.3 France Idiopathic Pulmonary Fibrosis Market, By Distribution Channel
    • 6.7.2 United Kingdom Idiopathic Pulmonary Fibrosis Market: Market Size and CAGR, 2018-2028 (USD Million & CAGR)
      • 6.7.2.1 United Kingdom Idiopathic Pulmonary Fibrosis Market, By Drug Type
      • 6.7.2.2 United Kingdom Idiopathic Pulmonary Fibrosis Market, By Route of Administration
      • 6.7.2.3 United Kingdom Idiopathic Pulmonary Fibrosis Market, By Distribution Channel
    • 6.7.3 Italy Idiopathic Pulmonary Fibrosis Market: Market Size and CAGR, 2018-2028 (USD Million & CAGR)
      • 6.7.3.1 Italy Idiopathic Pulmonary Fibrosis Market, By Drug Type
      • 6.7.3.2 Italy Idiopathic Pulmonary Fibrosis Market, By Route of Administration
      • 6.7.3.3 Italy Idiopathic Pulmonary Fibrosis Market, By Distribution Channel
    • 6.7.4 Spain Idiopathic Pulmonary Fibrosis Market: Market Size and CAGR, 2018-2028 (USD Million & CAGR)
      • 6.7.4.1 Spain Idiopathic Pulmonary Fibrosis Market, By Drug Type
      • 6.7.4.2 Spain Idiopathic Pulmonary Fibrosis Market, By Route of Administration
      • 6.7.4.3 Spain Idiopathic Pulmonary Fibrosis Market, By Distribution Channel
    • 6.7.5 Germany Idiopathic Pulmonary Fibrosis Market: Market Size and CAGR, 2018-2028 (USD Million & CAGR)
      • 6.7.5.1 Germany Idiopathic Pulmonary Fibrosis Market, By Drug Type
      • 6.7.5.2 Germany Idiopathic Pulmonary Fibrosis Market, By Route of Administration
      • 6.7.5.3 Germany Idiopathic Pulmonary Fibrosis Market, By Distribution Channel
    • 6.7.6 Rest of Europe Idiopathic Pulmonary Fibrosis Market: Market Size and CAGR, 2018-2028 (USD Million & CAGR)
      • 6.7.6.1 Rest of Europe Idiopathic Pulmonary Fibrosis Market, By Drug Type
      • 6.7.6.2 Rest of Europe Idiopathic Pulmonary Fibrosis Market, By Route of Administration
      • 6.7.6.3 Rest of Europe Idiopathic Pulmonary Fibrosis Market, By Distribution Channel

7. Asia-Pacific Idiopathic Pulmonary Fibrosis Market: Historic and Forecast (2018-2028)

  • 7.1 Asia-Pacific Idiopathic Pulmonary Fibrosis Market: Snapshot
  • 7.2 Asia-Pacific Idiopathic Pulmonary Fibrosis Market: Market Size and CAGR, 2018-2028 (USD Million & CAGR)
  • 7.3 Asia-Pacific Idiopathic Pulmonary Fibrosis Market: Key Factors
  • 7.4 Asia-Pacific Idiopathic Pulmonary Fibrosis Market Segmentation: By Drug Type
    • 7.4.1 Asia-Pacific Idiopathic Pulmonary Fibrosis Market, By Drug Type Overview
    • 7.4.2 Asia-Pacific Idiopathic Pulmonary Fibrosis Market Size, By Pirfenidone, By Value, 2018H-2028F (USD Million & CAGR)
    • 7.4.3 Asia-Pacific Idiopathic Pulmonary Fibrosis Market Size, By Nintedanib, By Value, 2018H-2028F (USD Million & CAGR)
    • 7.4.4 Asia-Pacific Idiopathic Pulmonary Fibrosis Market Size, By Other drugs, By Value, 2018H-2028F (USD Million & CAGR)
  • 7.5 Asia-Pacific Idiopathic Pulmonary Fibrosis Market Segmentation: By Route of Administration
    • 7.5.1 Asia-Pacific Idiopathic Pulmonary Fibrosis Market, By Route of Administration Overview
    • 7.5.2 Asia-Pacific Idiopathic Pulmonary Fibrosis Market Size, By Oral, By Value, 2018H-2028F (USD Million & CAGR)
    • 7.5.3 Asia-Pacific Idiopathic Pulmonary Fibrosis Market Size, By Parenteral, By Value, 2018H-2028F (USD Million & CAGR)
    • 7.5.4 Asia-Pacific Idiopathic Pulmonary Fibrosis Market Size, By Other ROA, By Value, 2018H-2028F (USD Million & CAGR)
  • 7.6 Asia-Pacific Idiopathic Pulmonary Fibrosis Market Segmentation: By Distribution Channel
    • 7.6.1 Asia-Pacific Idiopathic Pulmonary Fibrosis Market, By Distribution Channel Overview
    • 7.6.2 Asia-Pacific Idiopathic Pulmonary Fibrosis Market Size, By Hospital Pharmacies, By Value, 2018H-2028F (USD Million & CAGR)
    • 7.6.3 Asia-Pacific Idiopathic Pulmonary Fibrosis Market Size, By Retail Pharmacies, By Value, 2018H-2028F (USD Million & CAGR)
    • 7.6.4 Asia-Pacific Idiopathic Pulmonary Fibrosis Market Size, By Online Channel, By Value, 2018H-2028F (USD Million & CAGR)
  • 7.7 Asia-Pacific Idiopathic Pulmonary Fibrosis Market Segmentation: By Country
    • 7.7.1 China Idiopathic Pulmonary Fibrosis Market: Market Size and CAGR, 2018-2028 (USD Million & CAGR)
      • 7.7.1.1 China Idiopathic Pulmonary Fibrosis Market, By Drug Type
      • 7.7.1.2 China Idiopathic Pulmonary Fibrosis Market, By Route of Administration
      • 7.7.1.3 China Idiopathic Pulmonary Fibrosis Market, By Distribution Channel
    • 7.7.2 Japan Idiopathic Pulmonary Fibrosis Market: Market Size and CAGR, 2018-2028 (USD Million & CAGR)
      • 7.7.1.1 Japan Idiopathic Pulmonary Fibrosis Market, By Drug Type
      • 7.7.1.2 Japan Idiopathic Pulmonary Fibrosis Market, By Route of Administration
      • 7.7.1.3 Japan Idiopathic Pulmonary Fibrosis Market, By Distribution Channel
    • 7.7.3 South Korea Idiopathic Pulmonary Fibrosis Market: Market Size and CAGR, 2018-2028 (USD Million & CAGR)
      • 7.7.3.1 South Korea Idiopathic Pulmonary Fibrosis Market, By Drug Type
      • 7.7.3.2 South Korea Idiopathic Pulmonary Fibrosis Market, By Route of Administration
      • 7.7.3.3 South Korea Idiopathic Pulmonary Fibrosis Market, By Distribution Channel
    • 7.7.4 India Idiopathic Pulmonary Fibrosis Market: Market Size and CAGR, 2018-2028 (USD Million & CAGR)
      • 7.7.4.1 India Idiopathic Pulmonary Fibrosis Market, By Drug Type
      • 7.7.4.2 India Idiopathic Pulmonary Fibrosis Market, By Route of Administration
      • 7.7.4.3 India Idiopathic Pulmonary Fibrosis Market, By Distribution Channel
    • 7.7.5 Rest of Asia-Pacific Idiopathic Pulmonary Fibrosis Market: Market Size and CAGR, 2018-2028 (USD Million & CAGR)
      • 7.7.5.1 Rest of Asia-Pacific Idiopathic Pulmonary Fibrosis Market, By Drug Type
      • 7.7.5.2 Rest of Asia-Pacific Idiopathic Pulmonary Fibrosis Market, By Route of Administration
      • 7.7.5.3 Rest of Asia-Pacific Idiopathic Pulmonary Fibrosis Market, By Distribution Channel

8. Middle-East & Africa Idiopathic Pulmonary Fibrosis Market: Historic and Forecast (2018-2028)

  • 8.1 Middle-East & Africa Idiopathic Pulmonary Fibrosis Market: Snapshot
  • 8.2 Middle-East & Africa Idiopathic Pulmonary Fibrosis Market: Market Size and CAGR, 2018-2028 (USD Million & CAGR)
  • 8.3 Middle-East & Africa Idiopathic Pulmonary Fibrosis Market: Key Factors
  • 8.4 Middle-East & Africa Idiopathic Pulmonary Fibrosis Market Segmentation: By Drug Type
    • 8.4.1 Middle-East & Africa Idiopathic Pulmonary Fibrosis Market, By Drug Type Overview
    • 8.4.2 Middle-East & Africa Idiopathic Pulmonary Fibrosis Market Size, By Pirfenidone, By Value, 2018H-2028F (USD Million & CAGR)
    • 8.4.3 Middle-East & Africa Idiopathic Pulmonary Fibrosis Market Size, By Nintedanib, By Value, 2018H-2028F (USD Million & CAGR)
    • 8.4.4 Middle-East & Africa Idiopathic Pulmonary Fibrosis Market Size, By Other drugs, By Value, 2018H-2028F (USD Million & CAGR)
  • 8.5 Middle-East & Africa Idiopathic Pulmonary Fibrosis Market Segmentation: By Route of Administration
    • 8.5.1 Middle-East & Africa Idiopathic Pulmonary Fibrosis Market, By Route of Administration Overview
    • 8.5.2 Middle-East & Africa Idiopathic Pulmonary Fibrosis Market Size, By Oral, By Value, 2018H-2028F (USD Million & CAGR)
    • 8.5.3 Middle-East & Africa Idiopathic Pulmonary Fibrosis Market Size, By Parenteral, By Value, 2018H-2028F (USD Million & CAGR)
    • 8.5.4 Middle-East & Africa Idiopathic Pulmonary Fibrosis Market Size, By Other ROA, By Value, 2018H-2028F (USD Million & CAGR)
  • 8.6 Middle-East & Africa Idiopathic Pulmonary Fibrosis Market Segmentation: By Distribution Channel
    • 8.6.1 Middle-East & Africa Idiopathic Pulmonary Fibrosis Market, By Distribution Channel: Overview
    • 8.6.2 Middle-East & Africa Idiopathic Pulmonary Fibrosis Market Size, By Hospital Pharmacies, By Value, 2018H-2028F (USD Million & CAGR)
    • 8.6.3 Middle-East & Africa Idiopathic Pulmonary Fibrosis Market Size, By Retail Pharmacies, By Value, 2018H-2028F (USD Million & CAGR)
    • 8.6.4 Middle-East & Africa Idiopathic Pulmonary Fibrosis Market Size, By Online Channel, By Value, 2018H-2028F (USD Million & CAGR)

9. Market Dynamics

  • 9.1 Impact Assessment of Market Dynamics on the Global Idiopathic Pulmonary Fibrosis Market
  • 9.2 Drivers
  • 9.3 Restraints
  • 9.4 Trends

10. Industry Ecosystem Analysis

  • 10.1 Macro-Economic Factor Assessment
  • 10.2 Porter's Five Forces Model

11. Competitive Positioning

  • 11.1 Companies' Product Positioning
  • 11.2 Market Position Matrix
  • 11.3 Market Share Analysis of Idiopathic Pulmonary Fibrosis Market
  • 11.4 Company Profiles
    • 11.4.1 Boehringer Ingelheim
    • 11.4.2 F. Hoffmann-La Roche AG
    • 11.4.3 Cipla Ltd.
    • 11.4.4 Shionogi & Co., Ltd.
    • 11.4.5 Bristol-Myers Squibb Co.
    • 11.4.6 United Therapeutics
    • 11.4.7 FibroGen, Inc.
    • 11.4.8 Pliant Therapeutics
    • 11.4.9 Galecto Inc.
    • 11.4.10 CSL Behring